Fresenius Kabi Logo
  • Latest Biosimilars News
  • Contact Us
USA
Current website:
Fresenius Kabi Biosimilars
Suggested websites based on your location:
Fresenius Kabi USA - We Are Committed to Life
Global Website:
Fresenius Kabi Global Website

Fresenius Kabi around the world

  • Africa & Middle East
    • MENA
    • South Africa
  • Asia Pacific
    • Australia
    • China
    • China (Hong Kong SAR)
    • India
    • Indonesia
    • Japan
    • Korea
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • Taiwan
    • Thailand
    • Vietnam
  • Europe
    • Austria
    • Belgium
    • Croatia
    • Czech Republic
    • Denmark
    • Finland
    • France
    • Germany
    • Great Britain
    • Hungary
    • Ireland
    • Italy
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russian Federation
    • Slovakia
    • Spain
    • Sweden
    • Switzerland
  • Latin America
    • Argentina
    • Brazil
    • Chile
    • Colombia
    • Ecuador
    • Mexico
    • Peru
  • North America
    • Canada
    • USA
Fresenius Group
  • Why Fresenius Kabi
    • Main menu Why Fresenius Kabi

      Discover the history behind our areas of therapeutic expertise, patient-centric biosimilar development, state-of-the-art production, and rigorous testing.  

      • Our Advantage | Fresenius Kabi Our History

        Our commitment to deliver high-quality biosimilars is built on more than 100 years of expertise across numerous therapeutic areas. See what we have to offer today.

      • Our Advantage | Fresenius Kabi Patient-Centric Biosimilar Development

        We strive to ease the healthcare burden with affordable biologic medicine. Learn more about our biosimilar products.

      • Our Advantage | Fresenius Kabi State-of-the-Art Production

        We power our operations with dedicated commercial teams in various disciplines such as R&D, manufacturing and supply chain management.

      • Our Advantage | Fresenius Kabi Rigorous Testing

        Learn about the analytical methods we use to assess drug characteristics for biosimilarity between the biosimilar candidate and the reference product.

  • Our Portfolio of Biosimilars
    • Main menu Our Portfolio of Biosimilars

      Learn more about our approved biosimilar products in rheumatology, oncology, endocrinology, gastroenterology, and dermatology. Explore our biosimilars pipeline.

      • Our Biosimilar Portfolio Our Approved Products

        Our comprehensive portfolio of high-quality medicines has been developed with proven similarity in efficacy, safety, and immunogenicity to their reference products.

        • Our Approved Products Adalimumab-aacf

          Learn about the indications, biosimilarity to Humira® (adalimumab), dosing & administration, and patient support options. View information for patients & caregivers.

          • Adalimumab-aacf | Fresenius Kabi Totality of Evidence

            See the biosimilarity data for Adalimumab-aacf.

          • Adalimumab-aacf | Fresenius Kabi Dosing & Administration

            Read about how Adalimumab-aacf is administered and its dosage.

          • Adalimumab-aacf | Fresenius Kabi Support & Resources

            Discover patient assistance options to access Adalimumab-aacf. Download guides and brochures.

          • Adalimumab-aacf | Fresenius Kabi For Patients & Caregivers

            Understand how Adalimumab-aacf works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • Adalimumab-aacf | Fresenius Kabi Important Safety Information

            Important Safety Information

          • Adalimumab-aacf | Fresenius Kabi Full Prescribing Information

            Full Prescribing Information

        • Our Approved Products BOMYNTRA® (denosumab-bnht)

          Learn about the indications, biosimilarity to Xgeva® (denosumab), dosing & administration, and patient support options. View information for patients & caregivers.

          • BOMYNTRA® (denosumab-bnht) Totality of Evidence

            See the biosimilarity data for BOMYNTRA.

          • BOMYNTRA® (denosumab-bnht) Dosing & Administration

            Read about how BOMYNTRA is administered and its dosage.

          • BOMYNTRA® (denosumab-bnht) Support & Resources

            Discover patient assistance options to access BOMYNTRA. Download guides and brochures.

          • BOMYNTRA® (denosumab-bnht) For Patients & Caregivers

            Understand how BOMYNTRA works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • BOMYNTRA® (denosumab-bnht) Important Safety Information

            Important Safety Information

          • BOMYNTRA® (denosumab-bnht) Full Prescribing Information

            Full Prescribing Information

        • Our Approved Products CONEXXENCE® (denosumab-bnht)

          Learn about the indications, biosimilarity to Prolia® (denosumab), dosing & administration, and patient support options. View information for patients & caregivers.

          • CONEXXENCE® (denosumab-bnht) Totality of Evidence

            See the biosimilarity data for CONEXXENCE.

          • CONEXXENCE® (denosumab-bnht) Dosing & Administration

            Read about how CONEXXENCE is administered and its dosage.

          • CONEXXENCE® (denosumab-bnht) Support & Resources

            Discover patient assistance options to access CONEXXENCE. Download guides and brochures.

          • CONEXXENCE® (denosumab-bnht) For Patients & Caregivers

            Understand how CONEXXENCE works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • CONEXXENCE® (denosumab-bnht) Important Safety Information

            Important Safety Information

          • CONEXXENCE® (denosumab-bnht) Full Prescribing Information

            Full Prescribing Information

        • Our Approved Products OTULFI® (ustekinumab-aauz)

          Learn about the indications, biosimilarity to Stelara® (ustekinumab), dosing & administration, and patient support options. View information for patients & caregivers.

          • OTULFI® (ustekinumab-aauz) Totality of Evidence

            See the biosimilarity data for OTULFI.

          • OTULFI® (ustekinumab-aauz) Dosing & Administration

            Read about how OTULFI is administered and its dosage.

          • OTULFI® (ustekinumab-aauz) Support & Resources

            Discover patient assistance options to access OTULFI. Download guides and brochures.

          • OTULFI® (ustekinumab-aauz) For Patients & Caregivers

            Understand how OTULFI works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • OTULFI® (ustekinumab-aauz) Important Safety Information

            Important Safety Information

          • OTULFI® (ustekinumab-aauz) Full Prescribing Information

            Full Prescribing Information

        • Our Approved Products STIMUFEND® (pegfilgrastim-fpgk)

          Learn about the indication, biosimilarity to Neulasta®, dosing & administration and patient support options. View information for patients & caregivers.

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi Totality of Evidence

            See the biosimilarity data for STIMUFEND.

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi Dosing & Administration

            Read about how STIMUFEND is administered and its dosage.

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi Support & Resources

            Discover patient assistance options to access STIMUFEND. Download guides and brochures.

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi For Patients & Caregivers

            Understand how STIMUFEND works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi Important Safety Information

            Important Safety Information

          • STIMUFEND® (pegfilgrastim-fpgk) | Fresenius Kabi Full Prescribing Information

            Full Prescribing Information

        • Our Approved Products TYENNE® (tocilizumab-aazg)

          Learn about TYENNE® (tocilizumab-aazg), the first FDA-approved biosimilar for Actemra® (tocilizumab) made by Fresenius Kabi. See safety, dosing, and full prescribing info.

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi Totality of Evidence

            See the biosimilarity data for TYENNE.

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi Dosing & Administration

            Read about how TYENNE is administered and its dosage.

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi Support & Resources

            Discover patient assistance options to access TYENNE. Download guides and brochures.

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi For Patients & Caregivers

            Understand how TYENNE works. Learn about biosimilars. Download the patient and biosimilars brochure.

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi Important Safety Information

            Important Safety Information

          • TYENNE® (tocilizumab-aazg) | Fresenius Kabi Full Prescribing Information

            Full Prescribing Information

      • Our Biosimilar Portfolio Our Pipeline

        View our pipeline of biosimilars in the areas of immunology, oncology, hematology and endocrinology.

  • Patient Support & Access
    • Main menu Patient Support & Access

      See how we partner with healthcare providers and patients, and explore the benefits of our dedicated patient support program. 

      • Patient Support and Access | Fresenius Kabi Partnerships in Development & Treatment

        See who we work with to develop, manufacture and commercialize biosimilar products.

      • Patient Support and Access | Fresenius Kabi KabiCare Patient Support Program

        Our patient support program was developed with input from patients. Explore assistance options related to enrollment, insurance and therapy.

  • Resources
    • Main menu Resources

      Download guides, watch our videos and discover useful links.

  1. Our Portfolio of Biosimilars
  2. Our Approved Products
  3. TYENNE® (tocilizumab-aazg)

Important Safety Information

  • Why Fresenius Kabi
  • Our Portfolio of Biosimilars
  • Patient Support & Access
  • Resources
  • Latest Biosimilars News
  • Contact Us
Linkedin
  • Privacy Notice
  • Terms of Use
  • Data Privacy Contact
  • Cookie Notice
  • Imprint
  • Consumer Health Data Privacy Notice Supplement
  • Limit The Use of My Sensitive Personal Information
  • Accessibility Statement

© 2025 Fresenius Kabi USA, LLC. All Rights Reserved.
TYENNE and KABICARE are registered trademarks of Fresenius Kabi. Other trademarks are the property of their respective owners.

6056-TYEN-08-05/25 v1.0